FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2210102018> ?p ?o ?g. }

• W2210102018 endingPage "91" @default.
• W2210102018 startingPage "87" @default.
• W2210102018 abstract "Objective: Drugs currently in use for the management of heparin-induced thrombocytopenia (HIT) have their limitations. Several new oral anticoagulants (NOACs) such as dabigatran, rivaroxaban and apixaban may offer attractive therapy options for HIT. Although the clinical data are sparse on this topic, we have summarized the available clinical data, discussed pertinent in-vitro studies and provided the rational and advantages of using NOACs in patients with suspected or confirmed HIT. We have also reviewed the safety and efficacy of these NOACs in patients with HIT based on published literature. Methods: We reviewed all suspected or confirmed HIT cases treated with NOACs and indexed in English language in MEDLINE and EMBASE by July 2015. The bibliography of each relevant article was searched for additional reports. In-vitro studies and other pertinent literature were briefly discussed. Results: A total of 36 HIT patients were treated with the following NOACs: rivaroxaban (50%), dabigatran (36%) and apixaban (14%). Sixty-one percent of patients received argatroban bolus before NOACs and 3% received rivaroxaban after a lack of response with three-day course of fondaparinux. Three percent (n=1) received rivaroxaban after the patient responded to intravenous immunoglobulin for 2 days, following a lack of response to fondaparinux and bilvalirudin. In another 3% (n=1), prophylactic dose of rivaroxaban was used for 21 days and then changed to dabigatran because of persistent thrombocytopenia. All cases responded with early signs of clinical improvement and increase in platelet counts. A follow-up after a median 47 days (range 4- 450) reported no bleeding or thrombotic complications. Conclusion: In this review, all patients with HIT treated with NOACs responded without any bleeding or thrombotic complication. Although the argatroban bolus might have contributed to a response in some patients, response to NOAC alone in other patients and in-vitro studies provide a proof of principle that NOACs can be effective in the management of HIT. Additionally, properties such as rapid onset of action, oral administration, ease of use and a lack of need for monitoring make these drugs attractive options for HIT. However, given several limitations of prior reports, further confirmation of the results are desirable. Keywords: Apixaban, argatroban, dabigatran, heparin-induced thrombocytopenia, new oral anticoagulants, rivaroxaban." @default.
• W2210102018 created "2016-06-24" @default.
• W2210102018 creator A5000243266 @default.
• W2210102018 creator A5000485049 @default.
• W2210102018 creator A5039171417 @default.
• W2210102018 creator A5051793137 @default.
• W2210102018 creator A5072016547 @default.
• W2210102018 date "2015-12-17" @default.
• W2210102018 modified "2023-09-23" @default.
• W2210102018 title "New Oral Anticoagulants for the Management of Heparin Induced Thrombocytopenia: A Focused Literature Review" @default.
• W2210102018 cites W124032993 @default.
• W2210102018 cites W1505168661 @default.
• W2210102018 cites W1608345077 @default.
• W2210102018 cites W1641772231 @default.
• W2210102018 cites W1982041993 @default.
• W2210102018 cites W1982825827 @default.
• W2210102018 cites W2007933904 @default.
• W2210102018 cites W2027754441 @default.
• W2210102018 cites W2056795528 @default.
• W2210102018 cites W2057815045 @default.
• W2210102018 cites W2066868803 @default.
• W2210102018 cites W2071662133 @default.
• W2210102018 cites W2074722143 @default.
• W2210102018 cites W2078260919 @default.
• W2210102018 cites W2083217092 @default.
• W2210102018 cites W2085071414 @default.
• W2210102018 cites W2086581412 @default.
• W2210102018 cites W2087251835 @default.
• W2210102018 cites W2090823233 @default.
• W2210102018 cites W2098587138 @default.
• W2210102018 cites W2113089341 @default.
• W2210102018 cites W2130547360 @default.
• W2210102018 cites W2140569331 @default.
• W2210102018 cites W2142914264 @default.
• W2210102018 cites W2155960127 @default.
• W2210102018 cites W2160000345 @default.
• W2210102018 cites W2164580314 @default.
• W2210102018 cites W2170199903 @default.
• W2210102018 cites W2221498439 @default.
• W2210102018 cites W2031809468 @default.
• W2210102018 doi "https://doi.org/10.2174/187152571302151217124551" @default.
• W2210102018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26695419" @default.
• W2210102018 hasPublicationYear "2015" @default.
• W2210102018 type Work @default.
• W2210102018 sameAs 2210102018 @default.
• W2210102018 citedByCount "8" @default.
• W2210102018 countsByYear W22101020182016 @default.
• W2210102018 countsByYear W22101020182017 @default.
• W2210102018 countsByYear W22101020182019 @default.
• W2210102018 countsByYear W22101020182020 @default.
• W2210102018 crossrefType "journal-article" @default.
• W2210102018 hasAuthorship W2210102018A5000243266 @default.
• W2210102018 hasAuthorship W2210102018A5000485049 @default.
• W2210102018 hasAuthorship W2210102018A5039171417 @default.
• W2210102018 hasAuthorship W2210102018A5051793137 @default.
• W2210102018 hasAuthorship W2210102018A5072016547 @default.
• W2210102018 hasConcept C126322002 @default.
• W2210102018 hasConcept C177713679 @default.
• W2210102018 hasConcept C2776301958 @default.
• W2210102018 hasConcept C2776472838 @default.
• W2210102018 hasConcept C2776877702 @default.
• W2210102018 hasConcept C2777292125 @default.
• W2210102018 hasConcept C2777557582 @default.
• W2210102018 hasConcept C2778661090 @default.
• W2210102018 hasConcept C2778810321 @default.
• W2210102018 hasConcept C2779161974 @default.
• W2210102018 hasConcept C2779612170 @default.
• W2210102018 hasConcept C2780638905 @default.
• W2210102018 hasConcept C2780868729 @default.
• W2210102018 hasConcept C2991741193 @default.
• W2210102018 hasConcept C42219234 @default.
• W2210102018 hasConcept C71924100 @default.
• W2210102018 hasConcept C89560881 @default.
• W2210102018 hasConceptScore W2210102018C126322002 @default.
• W2210102018 hasConceptScore W2210102018C177713679 @default.
• W2210102018 hasConceptScore W2210102018C2776301958 @default.
• W2210102018 hasConceptScore W2210102018C2776472838 @default.
• W2210102018 hasConceptScore W2210102018C2776877702 @default.
• W2210102018 hasConceptScore W2210102018C2777292125 @default.
• W2210102018 hasConceptScore W2210102018C2777557582 @default.
• W2210102018 hasConceptScore W2210102018C2778661090 @default.
• W2210102018 hasConceptScore W2210102018C2778810321 @default.
• W2210102018 hasConceptScore W2210102018C2779161974 @default.
• W2210102018 hasConceptScore W2210102018C2779612170 @default.
• W2210102018 hasConceptScore W2210102018C2780638905 @default.
• W2210102018 hasConceptScore W2210102018C2780868729 @default.
• W2210102018 hasConceptScore W2210102018C2991741193 @default.
• W2210102018 hasConceptScore W2210102018C42219234 @default.
• W2210102018 hasConceptScore W2210102018C71924100 @default.
• W2210102018 hasConceptScore W2210102018C89560881 @default.
• W2210102018 hasIssue "2" @default.
• W2210102018 hasLocation W22101020181 @default.
• W2210102018 hasLocation W22101020182 @default.
• W2210102018 hasOpenAccess W2210102018 @default.
• W2210102018 hasPrimaryLocation W22101020181 @default.
• W2210102018 hasRelatedWork W2032118176 @default.
• W2210102018 hasRelatedWork W2090594031 @default.
• W2210102018 hasRelatedWork W2137088071 @default.

• next